State of Care for Neuromuscular Disease and Movement Disorders: Jess Holguin, OTD, OT/L
September 28th 2021The associate professor of clinical occupational therapy at USC Keck Hospital discussed the growing awareness for the care of these patients, as well as the integration of occupational therapists. [WATCH TIME: 2 minutes]
AMX0035’s Potential and Mechanism in ALS: Sabrina Paganoni, MD, PhD
September 28th 2021With AMX0035 expected to be submitted to the FDA for review in the coming months, the investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital chimed in to share her thoughts on its potential. [WATCH TIME: 3 minutes]
Mechanistic Action and FDA Outlook for Omaveloxolone in Friedreich Ataxia: David R. Lynch, MD, PhD
September 27th 2021The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]
Developing Interventions to Address Mental Health in Parkinson Disease: Lisanne Dommershuijsen, MSc
September 26th 2021The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]
COVID-19 Stressors and Mental Health in Parkinson Disease: Lisanne Dommershuijsen, MSc
September 25th 2021The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]
An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.
Anti-CD20 Utilization in Relapsing MS
Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.
Omavelexolone’s Potential in Friedreich Ataxia: David R. Lynch, MD, PhD
September 24th 2021The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedreich ataxia. [WATCH TIME: 2 minutes]
Ongoing Therapeutic Developments for Movement Disorders: Saar Anis, MD
September 23rd 2021When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]
Understanding the Use of Medical Cannabis for Movement Disorders: Saar Anis, MD
September 22nd 2021Following his presentation at the MDS Society Virtual Congress 2021, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center discussed his views on the use of medical cannabis. [WATCH TIME: 3 minutes]
Future Direction of AI, Neuroimaging Research: Michael Dwyer, PhD
September 22nd 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]
Studying Effects of Gender and Sex in Alzheimer Disease: Jessica Caldwell, PhD
September 21st 2021The director of The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed her recently awarded NIH grant and her work to understand why women are more likely to be impacted by Alzheimer disease.
Anti-CD20 Therapies for Relapsing MS
An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.
Selecting an S1P Modulator for Relapsing MS
Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.
Efficacy, Safety, and Tolerability of Apomorphine Sublingual Film: William Ondo, MD
September 17th 2021The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.